# US 10,865,415 B2 · Prevention, diagnosis and treatment of cancer overexpressing GPR160 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,865,415 B2 - Document ID: US10865415B2 - Status: Granted - Kind: B2 - Application number: 15/765,163 - Filed: 2016-09-29 - Published: 2019-02-21 - Granted: 2020-12-15 - Earliest claimed: 2015-09-30 - Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Inventors: Caihong Zhou; Xinchuan Dai; Mingwei Wang - Web page: https://patentgrep.com/patent/US10865415B2 ## CPC - C12N 15/1138: {against receptors or cell surface proteins} - A61K 31/713: Double-stranded nucleic acids or oligonucleotides - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - A61P 35/00: Antineoplastic agents - C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C12N 2310/14: interfering nucleic acids [NA] - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided are a dsRNA construct of an orphan G-protein-coupled receptor GPR160 gene related to prostate cancer and the use thereof, wherein the dsRNA construct of the GPR160 gene and a composition thereof can prevent or treat prostate cancer. ## Claims ### Claim 1 A dsRNA construct, wherein the dsRNA construct is double-stranded and the forward or reverse chain thereof has the structure shown in Formula I: SeqForward-X-SeqReverse Formula I wherein, Seqforward is a GPR160 gene fragment of SEQ ID NO: 6 or SEQ ID NO: 7; Seqreverse is a nucleotide sequence that is substantially complementary to Seqforward; X is a spacer sequence located between Seqforward and Seqreverse, and the spacer sequence is not complementary to Seqforward or Seqreverse. ### Claim 2 A dsRNA, wherein the dsRNA has the structure as shown in Formula II: wherein, Seq′forward is a RNA sequence corresponding to the GPR160 gene fragment sequence of SEQ ID NO: 6 or SEQ ID NO: 7; Seq′reverse is a sequence that is substantially complementary to Seq′forward; X′ is none, or a spacer sequence located between Seq′forward and Seq′reverse, and the spacer sequence is not complementary to Seq′forward and Seq′reverse, ll represents a hydrogen bond formed between Seq′forward and Seq′reverse. ### Claim 3 (depends on 1) A expression vector, wherein the expression vector comprises the dsRNA construct of claim 1. ### Claim 4 (depends on 1, 3) A host cell, wherein the host cell comprises the expression vector of claim 3 or has a DNA sequence corresponding to the dsRNA construct of claim 1 incorporated into its chromosome. ### Claim 5 A composition, wherein the composition contains an inhibitor inhibiting GPR160 gene expression by interfering with GPR160 gene fragment of SEQ ID NO: 6 or SEQ ID NO: 7; wherein the inhibitor includes: small interfering molecules or antisense nucleotides that specifically interfere with GPR160 gene expression. ### Claim 6 (depends on 1, 2, 5) The composition of claim 5, wherein the composition contains the dsRNA construct of claim 1 and/or the dsRNA of claim 2, and a pharmaceutically acceptable carrier. ### Claim 7 (depends on 5) The composition of claim 5, wherein the composition is a composition for inhibiting the expression of endogenous GPR160 gene in an animal. ### Claim 8 (depends on 1) A method for inhibiting GPR160 gene expression, comprising administering to a subject in need thereof an effective amount of the dsRNA construct of claim 1. ### Claim 9 A method for preparing dsRNA, including steps of: (i) preparing a construct expressing dsRNA, wherein the construct is double-stranded, and its sense or antisense strand contains the structure shown in Formula 1: SeqForward-X-SeqReverse Formula I wherein, Seqforward is a GPR160 gene fragment of SEQ ID NO: 6 or SEQ ID NO: 7; Seqreverse is a nucleotide sequence that is substantially complementary to Seqforward; X is a spacer sequence located between Seqforward and Seqreverse, and the spacer sequence is not complementary to Seqforward or Seqreverse; (ii) transferring the construct in step (i) into a host cell, thereby forming dsDNA as shown in Formula II in the host cell through expression, wherein, Seq′forward is a RNA sequence or sequence fragment corresponding to Seqforward; Seq′reverse is a sequence that is substantially complementary to Seq′forward; X′ is none, or a spacer sequence located between Seq′forward and Seq′reverse, and the spacer sequence is not complementary to Seq′forward or Seq′reverse, ll represents a hydrogen bond formed between Seq′forward and Seq′reverse. ### Claim 10 (depends on 9) The method of claim 9, wherein the spacer sequence X is 1-100 bp in length, preferably 4-10 bp. ### Claim 11 (depends on 10) The method of claim 10, wherein the GPR160 gene or GPR160 gene fragment is derived from mammal, preferably from human. ### Claim 12 A method for inhibiting GPR160 gene expression, comprising contacting cells expressing GPR160 with an effective amount of a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 7. ### Claim 13 (depends on 12) The method of claim 12, wherein the nucleic acid is an siRNA. ### Claim 14 (depends on 8) The method of claim 8, wherein the subject is a human patient having prostate cancer.